Results 31 to 40 of about 69,031,262 (351)
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
ACS Medicinal Chemistry Letters, 2020 While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis to GS-441524; GS-441524 is the predominant ...
Victoria C. Yan, F. Muller
semanticscholar +1 more source
Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: A Randomized Clinical Trial [PDF]
, 2022 Background: Open-label platform trials and a prospective meta-analysis suggest efficacy of anti–IL-6R therapies in hospitalized patients with COVID-19 receiving corticosteroids.
DiCioccio, A. Thomas +40 more
core +1 more source
A review of potential suggested drugs for coronavirus disease (COVID-19) treatment
European Journal of Pharmacology, 2021 The latest pandemic, coronavirus disease-2019 (COVID-19), is associated with high prevalence and easy transmission, which is expanding globally with no conventional treatment or vaccine. The new virus revealed 79% and 50% genomic similarities with severe
Parastoo Tarighi +5 more
semanticscholar +1 more source
Clinical trials on drug repositioning for COVID-19 treatment
Revista Panamericana De Salud Publica-pan American Journal of Public Health, 2020 The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported.
Sandro G. Viveiros-Rosa +1 more
semanticscholar +1 more source
American Journal of Epidemiology, 2022 Arterial blood oxygen saturation measured by pulse oximetry (SpO2) may be differentially less accurate for people with darker skin pigmentation, which could potentially affect COVID-19 treatment course. We analyzed pulse oximeter accuracy and association
S. Sudat +7 more
semanticscholar +1 more source
Revista Española de Quimioterapia, 2022 Current immune treatment directed to avoid viral replication relies mainly in convalescent plasma and monoclonal antibodies (mAbs). No clinical benefit for convalescent plasma has been reported in a meta-analysis and systematic review compared to standard of care.
Menendez, Rosario +3 more
openaire +3 more sources
International Journal of Antimicrobial Agents, 2020 Currently, there is no approved therapy for coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) therefore endorses supportive care only.
Priya Nori +12 more
semanticscholar +1 more source
Phytochemicals for the treatment of COVID-19 [PDF]
Journal of Microbiology, 2021 The coronavirus disease 2019 (COVID-19) pandemic has underscored the lack of approved drugs against acute viral diseases. Plants are considered inexhaustible sources of drugs for several diseases and clinical conditions, but plant-derived compounds have seen little success in the field of antivirals.
Españo, Erica +3 more
openaire +2 more sources
COVID‐19 treatment: A potential cause of acute pancreatitis
Clinical Case Reports, 2022 Remdesivir can precipitate fatal acute necrotizing pancreatitis especially in patients who previously suffer from hypertriglyceridemia.
Magdy Mohamed Allam +3 more
doaj +1 more source
2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update
Frontiers in Pharmacology, 2022 Treatment choices for the “severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2)” are inadequate, having no clarity on efficacy and safety profiles.
Zou-Fang Huang +6 more
semanticscholar +1 more source